Hepatitis E Virus in the Countries of the Middle East and North Africa Region: An Awareness of an Infectious Threat to Blood Safety

Soha Yazbek, Khalil Kreidieh and Sami Ramia

Department of Medical Laboratory Sciences, Faculty of Health Sciences, American University of Beirut, Lebanon

Corresponding Author: Sami Ramia, Medical Laboratory Sciences Program, Faculty of Health Sciences, American University of Beirut, P.O Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon, Tel: +961-1-350000 Ext: 4698, Fax: +961-1-744470; E-mail: sramia@aub.edu.lb

Received date: March 13, 2015, Accepted date: March 30, 2015, Published date: April 06, 2015

Abstract

Introduction: Hepatitis E virus (HEV) is mainly transmitted through contaminated water supplies which make the virus endemic in developing countries including countries of the Middle East and North Africa (MENA) region. Recent reports suggest potential risk of HEV transmission via blood transfusion particularly in endemic areas.

Materials and Methods: Related articles on HEV were collected by searching through the 25 countries of the MENA region using Pubmed and Medline within the past 14 years: January 2000-August 2014.

Results: One hundred articles were extracted, of which 25 were not eligible. The articles discussed the seroprevalence of HEV and HEV markers in 12 countries. Eight articles provided data on HEV in blood donors. The seroprevalence of HEV in the general MENA population ranged from 2.0%-37.5% and was higher in males than in females. Prevalence increased with age, but exposure seems to be in early life.

Discussion: In the MENA region the role of HEV as an infectious threat to blood safety is under-investigated. More data are needed to quantify the risk of transmission and to assess clinical outcomes. This requires, at least, surveillance screening of donors and recipients for HEV markers using sensitive and specific serological tests. At the present time, serious consideration should be given to selective screening for certain groups of patients (e.g. immunocompromised, pregnant women and others) who commonly require blood transfusion and are at high risk of hepatic failure or chronicity from HEV infection.

Keywords: Hepatitis E; HEV; MENA region; Epidemiology; Blood safety; Blood donors

Introduction

Hepatitis E virus (HEV) is a small (27-34 nm); non-enveloped, icosahedral, single stranded RNA virus of approximately 7.2 kb in length. Analysis of its RNA helicase and RNA-dependent RNA polymerase region shows that the virus forms a phylogenetically distinct group that was recently placed into a separate genus, Hepevirus in the Hepeviridae family [1,2]. The family contains mammalian HEV and a more distant avian HEV [3]. Phylogenetic analysis of the mammalian isolates showed that there are 4 major genotypes (genotypes 1-4) and several sub genotypes [4]. Each HEV genotype appears to have a specific geographic distribution: Genotypes 1 and 2 are restricted to humans and are mainly responsible for large mongooses) and are mainly responsible for sporadic cases of HEV in developed countries [5].

If HEV in developed countries is zoonotic and food-borne, mainly associated with eating uncooked or undercooked meat or viscera of deer, boars and pigs or by exposure to infected animals [14,15]. The true figure in many developing countries could be much higher than that reported since earlier studies used assays with poor sensitivity [16]. Higher results are expected when more sensitive assays are used [17]. Sera tested in recent IgG immunosassays based on a variety of HEV antigens gave broadly concordant results suggesting that antibodies detected are truly directed at HEV [18].

Seroprevalence of HEV

Rates of IgG positivity in a certain area are believed to be a reflection of the frequency of HEV infection in that area. However, estimating the burden of HEV infection in a population is not an easy task. The true figure in many developing countries could be much higher than that reported since earlier studies used assays with poor sensitivity [16]. Higher results are expected when more sensitive assays are used [17]. Sera tested in recent IgG immunosassays based on a variety of HEV antigens gave broadly concordant results suggesting that antibodies detected are truly directed at HEV [18].

In endemic areas, such as India and South-East Asia, studies on HEV seroprevalence have shown high frequencies in the general population, ranging from 27%-80% in the general population. In contrast, in non-endemic regions, seroprevalence varies from 2%-8% in Europe, Japan and South America to 18.0%-21.0% in the USA, Russia, UK, Southern France, Hong Kong, Korea, and China. In developing countries, water-borne epidemics of HEV mainly affect...
young adults, the clinical attack rate being highest among 15-35 year-old [19] and men are clinically infected 2-5 times more than women in most outbreaks [20]. Asymptomatic infections have been estimated to exceed the number of symptomatic cases by 2-4 times in waterborne outbreaks [21]. Although routine surveillance and reporting of HEV infection is far from universal and sensitive anti-HEV assays are still lacking, it is clear that the majority of disease burden due to HEV is in the low and medium income countries of Asia and Africa [22].

Mode(s) of transmission and endemicity

One of the earliest documented massive outbreaks of infectious hepatitis took place in New Delhi, India in late 1955 where at least 30,000 clinical cases of jaundice were reported with elevated morbidity and mortality in pregnant women [23]. Outbreaks with similar characteristics to the New Delhi outbreak were also documented in Kashmir Valley in 1978 [24] and in Afghanistan in 1983 [25]. All three outbreaks were associated with fecal-contamination of drinking water or flooding. In 1990-1991, the etiological agent of such outbreaks was isolated, partially cloned and was labelled hepatitis E virus [26]. HEV is now considered the leading cause of acute hepatitis worldwide and is considered endemic in developing countries.

Recent reports showed higher HEV seroprevalence in specific groups as paid blood donors and in repeatedly transmitted hemodialysis patients [27,28]. Furthermore, the recent reporting of transmission of HEV through blood transfusion from Saudi Arabia [29], Japan [30] and the UK [31] has led to the suggestion that the parenteral route could be an important route in the transmission of HEV. As early as 1996 we speculated on the possible transmission of HEV by blood transfusion in Saudi Arabia [32]. Since HEV is endemic in developing countries, including countries of the MENA region, the awareness of an infectious threat to blood safety is legitimate. The purpose of this manuscript, therefore, is to review the status of HEV in the MENA region countries and to see whether the transfusion-transmission route has been evaluated.

Materials and Methods

Related articles were collected, by searching through the countries of the MENA region. Over the past 14 years (from January 2000-August 2014); literature was reviewed using countries of the MENA region Pubmed and Medline. The search was conducted using predefined combination of keywords: “hepatitis E virus”, “hepatitis E”, “hepatitis E infection”, “blood donors” in combination with all the names of the countries of the MENA region. The MENA region includes 25 countries (Algeria, Bahrain, Cyprus, Djibouti, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, Turkey, UAE and Yemen) and covers a population of over 380 million people. One hundred articles were reviewed, of which 25 articles were excluded; the excluded papers were written in non-English language or had uninterpretable data (didn’t have seroprevalence data).

Results

HEV seroprevalence (anti-HEV IgG) and HEV markers, across age groups and in different categories of populations in various countries of the MENA region during the past 14 years are shown in Table 1.

There were eight articles published on HEV in blood donors (Table 2) of which only 2 studies performed HEV-RNA testing to see whether or not the donor was viremic at the time of donation. Only one study from Saudi Arabia was a prospective study [76]. Seroprevalence of HEV among the reported blood donors was within the range found in the general population except for one study from Saudi Arabia where 19% of the donors were anti-HEV positive [77].

Anti-HEV in Egypt exceeds 12.5% in children and can reach 84.0% in adults. In Iran, anti-HEV varies from region to another (2%-14%) but it does not exceed 14%. Similarly anti-HEV among Saudis varied from 4.0%-8.0% in the general population and in one study a seroprevalence of 19% was reported among blood donors. Regional variation in anti-HEV seroprevalence was also reported in the Turkish population (2%-13%) and anti-HEV was as high as 35% among agriculture workers. Anti-HEV variation (18%-22%) was reported among Iraqis and a seroprevalence of 11% was reported in Yemen. Molecular studies were not attempted in most of the studies reported. High HEV-RNA positivity was reported in pediatric patients with acute hepatitis in Egypt (23%), in hepatitis outbreaks in Sudan (20%-27%) in patients with chronic hepatitis C in Turkey (55%) and in pregnant women in UAE (30%).

| Country | Category/Population studied | Number of participants | Age (Mean group) | anti-HEV IgG (%) | anti-HEV IgM (%) | HEV RNA (%) | Referenc es |
|---------|----------------------------|-----------------------|-----------------|-----------------|----------------|-------------|------------|
| Egypt   | Outbreaks                   |                       |                 |                 |                |             |            |
| Assiut  |                           | 235                   | (2-54)          | -               | 24             | -           | [33]       |
| Egypt   | Hepatitis                   |                       |                 |                 |                |             |            |
| Patients who had a history of jaundice | 134                 | (20-40)             | 38              | -               | -             | [34]       |
| Pregnant women with chronic HCV infection | 56                  | 32.5 ± 12.3          | 71              | -               | -             | [35]       |
| Pregnant women free from chronic HCV infection | 60                  | 33.6 ± 7.8           | 47              | -               | -             | [35]       |
| Patients with acute on chronic liver disorders | 100                 | 46.38 ± 6.87         | 50              | 3               | 13            | [36]       |
| Patients suffering from hepatitis* | 50                   | (1.5-15)            | -               | -               | 0.50          | [37]       |
| Category                                      | Count | Age Range | ALT | Controls | 0.69 | 0 | 0.69 | 41 | 43 | 53 | 40 | 41 |
|----------------------------------------------|-------|-----------|-----|----------|------|---|------|----|----|----|----|----|
| Symptomatic acute hepatitis patients         | 235   | (1-65)    | -   | 16       | -    | 38|
| Asymptomatic contacts                       | 200   | -         | -   | 7        | -    | 38|
| Acute viral hepatitis patients               | 287   | -         | -   | 20       | 0.69 | 39|
| Patients with elevated liver enzymes         | 214   | 42.2 ± 8.6| -   | 2        | 0    | 40|
| Children with sporadic acute hepatitis       | 162   | 7.0 ± 2.0 | 39  | 2        | -    | 41|
| Healthy controls                             | 13    | 7.5 ± 1.5 | 0   | 0        | -    | 41|
| Inpatients with clinical acute viral hepatitis| 200   | 20.2 ± 14.2| (4-65)| - | 13 | - | 42|
| Pediatric patients with acute hepatitis      | 64    | (6-12)    | 13  | 17       | 23   | 43|
| Healthy children                             | 16    | (6-12)    | 13  | 0        | 0    | 43|
| Patients with ALT levels that were least twice the normal level | 47 | (2-77) | 85 | 2 | 0 | 44|
| HCV Cases                                    | 321   | (25-47)   | 56  | -        | -    | 45|
| non-HCV (controls)                           | 475   | (14-30)   | 51  | -        | -    | 45|
| Others                                       |       |           |     |          |      |    |
| Mothers                                      | 29    | -         | 31  | -        | -    | 46|
| Wastewater treatment plants workers          | 43    | 47.1 ± 3.7| 51  | -        | -    | 47|
| Comparison group                             | 43    | 48.2 ± 2.4| 30  | -        | -    | 47|
| Workers in wastewater treatment plants       | 205   | (20-40)   | 51  | -        | -    | 48|
| -                                           |       | (41-50)   | 43  | -        | -    | 48|
| -                                           |       | (51-60)   | 46  | -        | -    | 48|
| Aborted women                                |       | -         | 22  | 3        | 16   | 49|
| Villagers                                    | 919   | (5-75)    | 4   | -        | -    | 50|
| Pregnant women                               | 2428  | (16-48)   | 84  | -        | -    | 51|
| Communities in the Nile Delta and Upper Egypt| 10,026| (0->75)   | 68  | -        | -    | 52|
| Patients admitted to Children’s Hospital     | 68    | (6-12)    | 3   | 41       | 6    | 53|
| Iran                                         |       |           |     |          |      |    |
| Hemodialysis                                 |       |           |     |          |      |    |
| Hemodialysis patients                        | 80    | 55.69 ± (26-80) | 14.70 | 6 | - | - | 54|
| Healthy individuals (Control)                | 276   | 51.73 ± (24-77) | 15.10 | 3 | - | - | 54|
| Kidney transplant patients                   |       | -         | 30  | -        | -    | 55|
| Hemodialysis patients                        | 324   | 53.5 ± 15.1| 7   | -        | -    | 56|
| Others                                       |       |           |     |          |      |    |
| Pregnant women                               | 136   | (14-39)   | 4   | -        | -    | 57|
| **General population of Mashhad, north east of Iran** | 1582 | 29.06 ± 18.513 (<5 - ≥ 65) | 14 | - | - | [58] |
| HIV-infected patients | 100 | (34-43) | 10 | 0 | 0 | [59] |
| Population based (Tehran) | 551 | 41.28 ± 16.96 (1-83) | 9 | - | - | [60] |
| Active health centers in Khorramabad (Western Iran) | 400 | 36 (>20) | 8 | - | - | [61] |
| Community based (Sari district) | 1080 | (2-25) | 2 | - | - | [62] |
| Population-based (Isfahan Province) | 816 | (6- ≥ 50) | 4 | - | - | [63] |
| Population-based (Nahavand) | 1824 | 34.7 ± 19.5 (6->70) | 9 | - | - | [64] |

| **Outbreak** |  |  |  |  |  |  |
| Al-Sadr city, Baghdad | 270 | - | 21 | - | - | [65] |
| Al-Sadr city, Baghdad | 268 | (<10->40) | - | 38 | - | [66] |

| **Hepatitis** | 2,692 | (<5->45) | - | 2 | - | [67] |

| **Others** | 869 | (21-55) | 21 | 2 | - | [68] |
| Refugee Kurds from Iraq | 637 | 24 ± 8.4 (0.5-55) | 18 | - | - | [69] |

| **Israel** | 4,970 | 37 ± 14.2 | 0.38 | - | - | [70] |
| Backpackers to Tropical Countries | 105 | 22.3 ± 2.5 (<32) | 0 | - | - | [71] |

| **Hepatitis** | 246 | (<10->21) | - | 13 | - | [72] |

| **Hemodialysis** | 83 | 39.0 ± 17.8 (7-82) | 7 | 5 | - | [73] |
| Healthy controls | 400 | 40.3 ± 18.5 (10-78) | 11 | 0.30 | - | [73] |
| Patients from clinics | 64 | 42.5 ± 19.1 (6-75) | 13 | 2 | - | [73] |
| Patients admitted to wards | 113 | 49.8 ± 20.2 (14-95) | 11 | 0 | - | [73] |

| **Others** |  |  |  |  |  |  |
| Multiple transfused patients (retrospective) | 145 | 30.7 ± 17.3 (4-75) | 6 | 9 | 6 | [74] |
| Healthy controls (retrospective) | 250 | 27.1 ± 20.4 (2-76) | 4 | 0.80 | 0.80 | [74] |
| Transfused patients (prospective) | 25 | 31.5 ± 16.4 | 12 | 4 | - | [74] |
| Untransfused patients (prospective) | 25 | 29.5 ± 15.9 | 8 | 0 | - | [74] |

| **Sudan** |  |  |  |  |  |  |
| Darfur, Sudan Cases | 75 | (0->45) | 3 | 97 | - | [75] |
### Darfur, Sudan

| Control Group | 143 | (0->45) | 26 | 34 | - |
|----------------|-----|---------|----|----|---|
| Darfur, Sudan 20 | 20 | (15-44) | 90 | 95 | 20 |
| Darfur, Sudan T | 84 | - | 100 | 100 | 27 |

#### Hepatitis

| Pregnant women with features of acute viral hepatitis | 16 | 26.8 ± 7.1 | - | 50 | - |
|----------------|-----|-------------|----|----|---|
| Patients with fulminant hepatic failure | 37 | 38 (19-75) | - | 5 | - |

### Others

| Polytransfused patients | 107 | - | 29 | - | - |
|-------------------------|-----|----|----|---|---|
| Control group | 160 | - | 10 | - | - |
| Pregnant women | 404 | 30.08 ± 5.95 (17-52) | 12 | 0 | - |
| Population-based study | 1505 | 20.71 ± 1.96 (16-25) | 4 | - | - |

### Tunisia

#### Hepatitis

| Patients with chronic hepatitis B | 190 | 42.2 ± 9.1 (19–66) | 14 | 8 | 15 |
|-------------------------------|-----|---------------------|----|----|----|
| Patients with chronic hepatitis C | 174 | 47.2 ± 6.2 (21–72) | 54 | 6 | 55 |
| Control group | 178 | 37.2 ± 8.8 (18–55) | 16 | 7 | - |

#### Hemodialysis

| Hemodialysis patients | 92 | 55 ± 11 (22-71) | 21 | - | - |

### Turkey

#### Others

| Primary school children | 185 | (7-14) | 12 | - | - |
|------------------------|-----|-------|----|---|---|
| Primary school children | 515 | 9.6 ± 0.1 (6-13) | 2 | - | - |
| Community-based study | 582 | (>15) | 2 | - | - |
| Children after an earthquake | 589 | 11.5 ± 5.4 (0.5-17) | 0.30 | - | - |
| Pregnant women | 386 | 24.28 ± 4.58 | 7 | - | - |
| Children after an earthquake in Duzce | 383 | 8.8 ± 4.0 (2-15) | 5 | - | - |
| Children after an earthquake in Golyaka | 93 | 8.8 ± 3.0 (2-15) | 17 | - | - |
| Healthy children | 210 | 9.37 ± 7.31 (1-18) | 6 | - | - |
| Pregnant women | 245 | 26.3 ± 7.6 (17-41) | 13 | 0 | - |
| Control | 76 | 27.5 ± 3.4 (19-42) | 12 | 0 | - |
| Agricultural workers | 46 | 27.6 (15->40) | 35 | - | - |
| Control group | 45 | 28.5 (15->40) | 4 | - | - |
| Children | 340 | (5-16) | 9 | 7 | - |
| Patients with no acute hepatitis signs and symptoms | 1046 | 32.3 (15-75) | 4 | - | - |
| Pediatric age groups | 338 | - | 0.89 | - | - |
| Children | 909 | (0.5-15) | 2 | - | - |
HEV genotypes reported: *G3 T G1

Table 1: Hepatitis E virus (HEV) markers in different categories of populations in the middle east and north africa (MENA) countries.

| Country            | Number of participants | Mean age (Age group) | anti-HEV IgG (%) | anti-HEV IgM (%) | HEV RNA (%) | References |
|--------------------|------------------------|----------------------|------------------|-----------------|-------------|------------|
| Egypt              | 760                    | 23.8 ± 5.3           | 0.45             | 0.26            | [101]       |
| Iran               | 52                     | (34-44)              | 12               | 0               | [59]        |
|                   | 530                    | 36.3 ± 11.7 (18->50) | 14               | -               | [102]       |
|                   | 400                    | 33.3 (18-60)         | 12               | -               | [103]       |
| Saudi Arabia       | 900                    | 30 ± 7.8 (18-66)     | 19               | 4               | [105]       |
|                   | 107                    | -                    | 10               | 3               | [74]        |
| Tunisia            | 687                    | 32.6 ± 8.6           | 5                | -               | [106]       |

Table 2: Hepatitis E virus (HEV) markers among blood donors in the middle east and north africa (MENA) countries.

Discussion

In recent years, studies from developed countries have shown asymptomatic viremia (HEV-RNA) in blood donors which is suggestive of ongoing subclinical infection [107-109]. The presence of HEV RNA is in the serum of healthy donors indicates that there is a potential risk of transmission of HEV through blood and indeed transmission of HEV by transfusion has been reported on several occasions from Europe and Japan [110-114]. The first molecularly confirmed case of transfusion-transmitted HEV was reported in 2004 from Japan [112]. Other cases have been confirmed in Sweden, Germany and the United States [107,108], in the United Kingdom [110] and in France [111]; to mention only few. Recent articles have already reviewed the risk of HEV infection by blood donation from developed countries. The incidence of HEV in the blood donor population in developed countries however, is unclear and is likely underestimated and this could be possibly due to several factors including: 1) The lack of well-validated assays; 2) The asymptomatic nature of HEV infection among adults; 3) The lack of testing; 4) and finally the underreporting of HEV disease in all countries.

On the other hand, in endemic countries including countries of the MENA region, the impact of HEV transmission through blood transfusion has rarely been evaluated. The possibility of transmission through blood transfusion was based mainly on retrospective evaluation in transfusion recipients [115,116] and that multi transfused had significantly higher prevalence of markers for acute HEV (anti-IgM and HEV-RNA) as compared to controls [117-119]. In the MENA region, out of the 75 published articles that showed interpretable data during the past 14 years, only 8 articles provided data on HEV in blood donors: Seven of the articles reported on the seroprevalence of HEV in blood donors and only one study was prospective. Anti-HEV (IgG) in blood donors ranged from 5.4% among Tunisians to over 50% among Egyptians. In one study from Saudi Arabia, anti-HEV (IgG) in blood donors was as high as 19.0% (105). It is interesting to note that the blood donors in this Saudi study were from one location (Makkah) where the majority of the people drank well-water [105]. Moreover, 4.3% of the blood donors tested was anti-HEV (IgM) positive implicating HEV as a potential transfusion risk. In the prospective study from Saudi Arabia [74] HEV infection developed in 3 of 22 susceptible patients following blood transfusion. The infections were traced to infected donor samples (HEV-RNA-positive) and occurred within the incubation period of HEV infection. Thus asymptomatic viremia may occur in healthy adults in endemic areas and viremia and fecal shedding have been reported in symptom-free carriers. The available but scanty data therefore, show that the disease burden of HEV infection in blood donors in countries which experience outbreaks of HEV infection is grossly under-investigated. This fact, in addition to the high endemicity of HEV in developing...
countries, and the risk of transmission of HEV by transfusion documented in some developed countries lead to the emerging awareness of infectious threat to blood safety in developing countries.

As for the seroprevalence of HEV in the MENA region, published data during the past 14 years confirm the endemicity of HEV in all 12 MENA countries studied but data on the remaining 13 countries are still lacking. Except for Egypt where anti-HEV reaches 100% in certain populations, the seroprevalence of HEV in the general population ranges from 2.3%-37.5% and is higher in males than in females. Prevalence increased with age, but exposure seems to be in early life in Egypt as high prevalence was detected in young children. This increase in percentage of anti-HEV with age could be consistent with cumulative exposure to infection over time [120].

It must be emphasized however that our study suffers serious limitations. The major limitation is in the methodology of the reported studies where the selection of patients and the assays used were very different. Moreover, earlier assays used were less sensitive than the recent ones [121] which cast some doubt on the frequencies reported as underestimated and hence not representative. In addition, data on HEV on the remaining 13 countries of the MENA region are still missing. Furthermore, only three studies reported on HEV genotypes. In Egypt, genotype 1 [39] and genotype 3 [37] were found among hepatitis patients. In Sudan, genotype 3 was detected during an outbreak in Darfur [77]. More research is needed to identify the predominant genotype(s) in the various countries and even in the various populations of the MENA region.

It can be concluded that more extensive investigations are required to determine the disease burden of HEV infection in blood donors in developing countries. This will include exploring epidemiological, virological and cultural data in evaluating the potential risk of HEV infection via blood transfusion in these counties. National surveillance screening of donors and recipients for markers of recent HEV infection is of utmost importance. The reliability of the data depends on the reliability of the tests employed. IgM antibodies to HEV are present for several weeks following acute HEV infection [122] indicating that perhaps screening for HEV IgM class antibodies could be a marker for detecting active HEV infection. No infectivity data however, are available for IgM-positive donations. HEV-RNA on the other hand does not persist for long, becoming undetectable in blood three weeks after the onset of symptoms [123].

Although screening for HEV in blood donors is still not a universal requirement, selective screening is to be recommended in certain circumstances. Recent evidence shows that HEV infection can take a severe or even fatal course resulting in liver failure in immunocompromised, pregnant women or patients with chronic liver disease [122-126]. Since these patients often require blood transfusion, it is prudent them that screening for HEV-RNA or at least for anti-HEV IgM in donated blood for these patients should be implemented as soon as possible.

Acknowledgement

The authors would like to acknowledge Ms. Yasmine Abou Taha for English language editing, Ms. Maha Abul Naja for her secretarial, work and Ms. Rana Charide for her assistance.

References

1. Payne CJ, Ellis TM, Plant SL, Gregory AR, Wilcox GE (1999) Sequence data suggests big liver and spleen disease virus (BLSV) is genetically related to hepatitis E virus. Vet Microbiol 68: 119-125.
2. Chandra V, Kar-Roy A, Kumari S, Mayor S, Jameel S (2008) The hepatitis E virus ORF3 protein modulates epidermal growth factor receptor trafficking, STAT3 translocation, and the acute-phase response. J Virol 82: 7100-7110.
3. Huang FF, Haqshenas G, Shivasprasad HL, Guenette DK, Woolcock PR, et al. (2002) Heterogeneity and seroprevalence of a newly identified avian hepatitis e virus from chickens in the United States. J Clin Microbiol 40: 4197-4202.
4. Lu L, Li C, Hagedorn CH (2006) Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 16: 5-36.
5. Kamar N, Bendall R, Legrand-Abbravanel F, Xia NS, Ijaz S, et al. (2012) Hepatitis E. Lancet 379: 2477-2488.
6. Dalton HR, Bendall R, Ijaz S, Banks M (2008) Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 8: 698-709.
7. Dalton HR, Hunter JG, Bendall RP (2013) Hepatitis E. Curr Opin Infect Dis 26: 471-478.
8. Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, et al. (1997) A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U S A 94: 9860-9865.
9. Meng XJ, Dea S, Engle RE, Friendship R, Lyoo YS, et al. (1999) Prevalence of antibodies to the hepatitis E virus in pigs from countries where hepatitis E is common or is rare in the human population. J Med Virol 59: 297-302.
10. Wichmann O, Schimanski S, Koch J, Kohler M, Rothe C, et al. (2008) Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis 198: 1732-1741.
11. Dalton HR, Fellows HJ, Gane EJ, Wong P, Gerred S, et al. (2007) Hepatitis E in new zealand. J Gastroenterol Hepatol 22: 1236-1240.
12. Tsang TH, Denison EK, Williams HV, Venczel LV, Ginsberg MM, et al. (2000) Acute hepatitis E infection acquired in California. Clin Infect Dis 30: 618-619.
13. Mitsui T, Tsukamoto Y, Hirose A, Suzuki S, Yamazaki C, et al. (2006) Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis, patients on maintenance hemodialysis and healthy individuals in Japan. J Med Virol 78: 1015-1024.
14. Mizuo H, Yazaki Y, Sugawara K, Tsuda F, Takahashi M, et al. (2005) Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan. J Med Virol 76: 341-349.
15. Aggarwal R, Naik S (2009) Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol 24: 1484-1493.
16. Mansuy JM, Legrand-Abbravanel F, Calot JP, Peron JM, Alric L, et al. (2008) High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol 80: 289-293.
17. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Ilg W (2013) Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis 207: 497-500.
18. Bendall R, Ellis V, Ijaz S, Thurairajah P, Dalton HR (2008) Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response. J Med Virol 80: 95-101.
19. Purcell RH, Emerson SU (2008) Hepatitis E: an emerging awareness of an old disease. J Hepatol 48: 494-503.
20. Aggarwal R, Kumar R, Pal R, Naik S, Semwal SN, et al. (2002) Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area. Indian J Gastroenterol 21: 14-18.
21. Guthmann JP, Klovstad H, Boccia D, Hamid N, Pinoges L, et al. (2006) A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis 42: 1685-1691.
64. Taremi M, Mohammad Alizadeh AH, Ardalan A, Ansari S, Zali MR (2008) Seroprevalence of hepatitis E in Nahavand, Islamic Republic of Iran: a population-based study. East Mediterr Health J 14: 157-162.

65. Uba NM (2013) The prevalence of hepatitis E virus in Al-Sadr City - Baghdad. Clin Lab 59: 115-120.

66. Al-Nasrawi KK, Al Diwan JK, Al-Hadithi TS, Saleh AM (2010) Viral hepatitis E outbreak in Al-Sadr city, Baghdad, Iraq. East Mediterr Health J 16: 1128-1132.

67. Al-Naaimi AS, Turkm AM, Khaled HA, Jalil RW, Mkhlef OA, et al. (2012) Predicting Acute Viral Hepatitis Serum Markers (A and E) in Patients with Suspected Acute Viral Hepatitis Attending Primary Health Care Centers in Baghdad: A One Year Cross-Sectional Study. Glob J Health Sci 4: 172-183.

68. Aysit KS, Durupinar P, Marmmen MP Jr, Sirisopanana N, Rodkvamtook W, et al. (2007) Hepatitis E virus infection in Thai troops deployed with U.N. peacekeeping forces. Mil Med 172: 1217-1219.

69. Chironna M, Germinario C, Lopalo PL, Carrozziini F, Barbuti S, et al. (2003) Prevalence rates of viral hepatitis infections in refugee Kurds from Iraq and Turkey. Infection 31: 70-74.

70. Lachsh T, Tandlich M, Schwartz E (2013) Acute hepatitis in israeli travelers. J Travel Med 20: 232-236.

71. Potasman I, Koren L, Peterman M, Sruho I (2000) Lack of hepatitis E infection among backpackers to tropical countries. J Travel Med 7: 208-210.

72. Ayoola EA, Aderolu A, Gadour MO, Al-Hazmi M, Hamza MK, et al. (2001) Serological profile of sporadic acute viral hepatitis in an area of hyper-endemic hepatitis B virus infection. Saudi J Gastroenterol 7: 95-102.

73. Ayoola EA, Want MA, Gadour MO, Al-Hazmi MH, Hamza MK (2002) Hepatitis E virus infection in haemodialysis patients: a case-control study in Saudi Arabia. J Med Virol 66: 329-334.

74. Khuroo MS, Kamili S, Yattoo GN (2004) Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol 19: 778-784.

75. Guthmann JP, Klovstad H, Boccia D, Hamid N, Velipasaoglu S, et al. (2002) A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis 34: 1685-1691.

76. Boccia D, Guthmann JP, Klovstad H, Hamid N, Tatay M, et al. (2006) High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis 42: 1679-1684.

77. Nicand E, Armstrong GL, Enouf V, Guthmann JP, Guerin JP, et al. (2005) Genetic heterogeneity of hepatitis E virus in Darfur, Sudan, and neighboring Chad. J Med Virol 77: 519-521.

78. Ahmed RE, Karsany MS, Adami I (2008) Brief report: acute viral hepatitis and poor maternal and perinatal outcomes in pregnant Sudanese women. J Med Virol 80: 1747-1748.

79. Mudawi HM, Yousif BA (2007) Fulminant hepatic failure in an African setting: etiology, clinical course, and predictors of mortality. Dig Dis Sci 52: 3266-3269.

80. Hannahi N, Boughannmourea L, Marzouk M, Tifha M, Khill A, et al. (2011) [Viral infection risk in polytransfused adults: seroprevalence of hepatitis viruses in central Tunisia]. Bull Soc Pathol Exot 104: 220-225.

81. Hannahi N, Hidard S, Harbadi I, Mahalla S, Marzouk M, et al. (2011) [Seroprevalence and risk factors of hepatitis E among pregnant women in central Tunisia]. Pathol Biol (Paris) 59: e115-118.

82. Rezig D, Ouneissa R, Mhiri L, Mejri S, Haddad-Boubaker S, et al. (2008) [Seroprevalences of hepatitis A and E infections in Tunisia]. Pathol Biol (Paris) 56: 148-153.

83. Bayram A, Eksi F, Mehilli M, Sözen E (2007) Prevalence of hepatitis E virus antibodies in patients with chronic hepatitis B and chronic hepatitis C. Intervirology 50: 281-286.

84. Uçar E, Çetin M, Kuvandik C, Helvacı MR, Güllü M, et al. (2009) [Hepatitis E virus seropositivity in hemodialysis patients in Hatay province, Turkey]. Mikrobiyol Bul 43: 299-302.

85. Cevahir N, Demir M, Bozkurt AI, Ergin A, Kaleli I (2013) Seroprevalence of hepatitis E virus among primary school children. Pak J Med Sci 29: 629-632.

86. Maral I, Budakoglu IL, Ceyhan MN, Atak A, Bumin MA (2010) Hepatitis E virus seroepidemiology and its change during 1 year in primary school students in Ankara, Turkey. Clin Microbiol Infect 16: 831-835.

87. Eker A, Tansel O, Kunduracılar H, Tokuc B, Yüyükzural, et al. (2009) Hepatitis E virus epidemiology in adult population in Edirne province, Turkey. Mikrobiyol Bul 43: 251-258.

88. Kaya AD, Ozturk CE, Yavuz T, Ozaydin C, Bahcebasi T (2008) Changing patterns of hepatitis A and E sero-prevalences in children after the 1999 earthquakes in Duze, Turkey. J Paediatr Child Health 44: 205-207.

89. Oncu S, Oncu S, Oykay P, Ertug S, Sakarya S (2006) Prevalence and risk factors for HEV infection in pregnant women. Med Sci Monit 12: CR36-39.

90. Sencan I, Sahin I, Kaya D, Oksuz S, Yildirim M (2004) Assessment of HAV and HEV seroepidemiology in children living in post-earthquake Serops from Duzce, Turkey. Eur J Epidemiol 19: 461-465.

91. Atabek ME, Fındık Y, Gulyüz A, Erkul I (2004) Prevalence of anti-HAV and anti-HEV antibodies in Konya, Turkey. Health Policy 67: 265-269.

92. Cevrioglu AS, Altindis M, Tanir HM, Aksoy F (2004) Investigation of the incidence of hepatitis E virus among pregnant women in Turkey. J Obstet Gynaecol Res 30: 48-52.

93. Ceylan A, Ertem M, İlcin E, Özekinci T (2003) A special risk group for hepatitis E infection: Turkish agricultural workers who use untreated waste water for irrigation. Epidemiol Infect 131: 753-756.

94. Yaylı G, Kılıç S, Ormeci AR (2002) Hepatitis agents with enteric transmission—an epidemiological analysis. Infection 30: 334-337.

95. Cesur S, Akin K, Doğanlıoğlu I, Birengel S, Balık I (2002) [Hepatitis A and hepatitis E seroprevalence in adults in the Ankara area]. Mikrobiyol Bul 36: 79-83.

96. Colak D, Ogunc D, Gunseren F, Velpasaoğlu S, Aktekin MR, et al. (2002) Seroprevalence of antibodies to hepatitis A and E viruses in pediatric age groups in Turkey. Acta Microbiol Immunol Hung 49: 93-97.

97. Sidal M, Unüvar E, , Cihan C, Onel D, et al. (2001) Age-specific seroepidemiology of hepatitis E in Turkey. J Microbiol Immunol Infect 34: 241-247.

98. Bayram AA, Eksi F, Mehli M, Sözen E, et al. (2010) Seroprevalence of hepatitis A and hepatitis E infections in children in the London area. J Med Microbiol 59: 92-94.

99. Kumar RM, Uduman S, Rana S, Kochiyil JK, Usmani A, et al. (2001) Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. Eur J Obstet Gynecol Reprod Biol 100: 9-15.

100. Bawazir AA, Hart CA, Sallam TA, Parry CM, Beeching NJ, et al. (2010) Seroepidemiology of hepatitis A and hepatitis E viruses in Aden, Yemen. Trans R Soc Trop Med Hyg 104: 801-805.

101. Ibrahim EH, Abdelwahab SF, Nady S, Hashem M, Galal G, et al. (2011) Prevalence of anti-HEV IgM among blood donors in Egypt. J Immunol 187: 47-58.

102. Eltatham H, Ramezani A, Esfamari A, Sofian M, Banaeil M, et al. (2013) Sero-prevalence of Hepatitis E Virus infection among volunteer blood donors in central province of Iran in 2012. Iran J Microbiol 5: 172-176.

103. Assarehzadegan MA, Shahin AA, Ustad AM, Hussaini HS (2009) Hepatitis E: a common cause of acute viral hepatitis. J Pak Med Assoc 59: 92-94.

104. Kumar RM, Uduman S, Rana S, Kochiyil JK, Usmani A, et al. (2001) Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates. Eur J Obstet Gynecol Reprod Biol 100: 9-15.

105. Bawazir AA, Hart CA, Sallam TA, Parry CM, Beeching NJ, et al. (2010) Seroepidemiology of hepatitis A and hepatitis E viruses in Aden, Yemen. Trans R Soc Trop Med Hyg 104: 801-805.
106. Houcine N, Jacques R, Salma F, Anne-Gaëlle D, Amin S, et al. (2012) Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia. Clin Microbiol Infect 18: E119-121.

107. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, et al. (2012) Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol 50: 2708-2713.

108. Baylis SA, Gärtner T, Nick S, Overmyr J, Blümel J (2012) Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang 103: 89-90.

109. Dreier J, Juhl D2 (2014) Autochthonous hepatitis e virus infections: a new transfusion-associated risk? Transfus Med Hemother 41: 29-39.

110. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, et al. (2006) Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med 16: 79-83.

111. Colson P, Coze C, Gallian P, Henry M, De Micco P, et al. (2007) Transfusion-associated hepatitis E, France. Emerg Infect Dis 13: 648-649.

112. Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, et al. (2008) A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 48: 1368-1375.

113. Tamura A, Shimizu YK, Tanaka T, Kuroda K, Arakawa Y, et al. (2007) Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 37: 113-120.

114. Matsubayashi K, Sakata H, Ikeda H (2011) Hepatitis E virus infection and blood transfusion in Japan. ISBT Sci Ser 6: 344-349.

115. Arankalle VA, Chobe LP (2000) Retrospective analysis of blood transfusion recipients: evidence for post-transfusion hepatitis E. Vox Sang 79: 72-74.

116. Colson P, Coze C, Gallian P, Henry M, De Micco P, et al. (2007) Transfusion-associated hepatitis E, France. Emerg Infect Dis 13: 648-649.

117. Toyoda H, Honda T, Hayashi K, Kato Y, Goto H, et al. (2008) Prevalence of hepatitis E virus IgG antibody in Japanese patients with hemophilia. Intervirology 51: 21-25.

118. Irshad M, Peter S (2002) Spectrum of viral hepatitis in thalassemic children receiving multiple blood transfusions. Indian J Gastroenterol 21: 183-184.

119. Mitsui T, Tsukamoto Y, Yamazaki C, Masuko K, Tsuda F, et al. (2004) Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. J Med Virol 74: 563-572.

120. Dalton HR, Stableforth W, Thurairajah P, Hazeldine S, Remnarace R, et al. (2008) Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol 20: 784-790.

121. Mansuy JM, Bendall R, Legrand-Abravanel F, Sauné K, Miédouge M, et al. (2011) Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 17: 2309-2312.

122. Clayson ET, Myint KS, Smithian R, Vaughn DW, Innis BL, et al. (1995) Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 172: 927-933.

123. Nelson KE, Kmush B, Labrique AB (2011) The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients. Expert Rev Anti Infect Ther 9: 1133-1148.

124. Kamar N, Garrouste C, Haagema EB, Garrigue V, Pitschke S, et al. (2011) Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140: 1481-1489.

125. Neukam K, Barreiro P, Macías J, Avellón A, Cifuentes C, et al. (2013) Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis 57: 465-468.

126. Te HS, Drobeniuc J, Kamili S, Dong C, Hart J, et al. (2013) Hepatitis E virus infection in a liver transplant recipient in the United States: a case report. Transplant Proc 45: 810-813.